EpiPen Buyers Tear Into Mylan, Pfizer Bid For Cert. Review

Law360 (March 24, 2020, 5:50 PM EDT) -- EpiPen buyers suing Mylan and Pfizer over the exorbitant cost of the emergency allergy treatment are fighting the drugmakers' push for a Tenth Circuit review of their class certification win, arguing a mid-case appeal is only warranted in "death knell cases" and this isn't one of them.

The purchasers are battling the drugmakers' effort to secure an appellate review of last month's certification decision in which a Kansas federal judge certified two nationwide classes of consumers seeking damages for racketeering and state antitrust violations from Mylan and Pfizer.

However, the EpiPen buyers pointed out Monday that the Tenth Circuit has previously ruled that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!